The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
Rusfertide showed a 77% clinical response rate in polycythemia vera patients, significantly higher than the 33% with placebo. The drug reduced phlebotomy frequency, with 0.5 per patient in the ...
In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.
CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., March 02, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) today announced that the U.S. Food and ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule ...
Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...
Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...
Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s website. TipRanks is the most comprehensive data set of sell side ...
NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results